Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nano HoldingsTSE:4571 +0.97%39 Cash Ratio is 4.99 as of Mar. 2026, which is 67% below its 10-year median of 15.34. GuruFocus rates TSE:4571 with a GF Score™ of 39/100 and a GF Value™ of 円186.24 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,341 Biotechnology companies, Nano Holdings ranks better than 68.83% on this metric.
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Nano Holdings Cash Ratio Related Terms
Nano Holdings Cash Ratio Historical Data
* Premium members only.
The historical data trend for Nano Holdings's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4571 vs VRTX, REGN, RVMD: Cash Ratio Comparison
For the Biotechnology subindustry, Nano Holdings's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nano Holdings Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nano Holdings's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Nano Holdings's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nano Holdings (TSE:4571) has a Cash Ratio of 4.99 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Nano Holdings and its competitors. This is 67% below median its historical median of 15.34. Over the past decade, Nano Holdings' Cash Ratio has ranged from 2.91 to 50.34. According to the industry distribution chart, Nano Holdings ranks #418 out of 1341 companies in the Biotechnology industry, placing it in the top 31.2%.
Is Nano Holdings' Cash Ratio too high?
Nano Holdings' current Cash Ratio of 4.99 is 67% below median its 10-year median of 15.34. Over the past 10 years, this metric has ranged from a low of 2.91 to a high of 50.34. The Biotechnology industry median Cash Ratio is 3.00. Nano Holdings' value of 4.99 is 66.3% above this industry median. Based on the distribution chart, Nano Holdings ranks #418 out of 1341 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nano Holdings has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nano Holdings' Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nano Holdings ranks #418 out of 1341 companies for Cash Ratio. This puts Nano Holdings in the upper half of its industry. The industry median Cash Ratio is 3.00. Nano Holdings' value of 4.99 is 66.3% above this benchmark. Historically, Nano Holdings' own Cash Ratio has ranged from 2.91 to 50.34 over the past decade. While the company's 10-year median is 15.34 vs. the industry median of 3.00, Nano Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 3.00, based on 1,341 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nano Holdings's current Cash Ratio of 4.99 is 66.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Nano Holdings and its competitors. For the Biotechnology industry, the median Cash Ratio is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nano Holdings's current Cash Ratio is 4.99, which is 67% below median its own 10-year median of 15.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nano Holdings stock overvalued right now?
Based on GuruFocus' analysis, Nano Holdings (TSE:4571) is currently considered Possible Value Trap. The stock's GF Value™ is 円186.24, compared to a current price of 円104.00 — trading 44.2% below its estimated fair value. The current Cash Ratio is 4.99, which is 67% below median its 10-year median of 15.34 and 66.3% above the Biotechnology industry median of 3.00. Nano Holdings' overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Nano Holdings (TSE:4571), the current Cash Ratio is 4.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nano Holdings (TSE:4571) Overvalued in 2026?
Based on GuruFocus' analysis, Nano Holdings stock appears to be undervalued.
The current stock price of 円104.00 is trading 44.2% below its estimated GF Value™ of 円186.24.
GuruFocus considers Nano Holdings to be Possible Value Trap.
Key valuation signals for TSE:4571:
Cash Ratio: 4.99 (67% below median its 10-year median of 15.34)
GF Value™: 円186.24 vs. price of 円104.00 (44.2% below fair value)
Industry Position: 66.3% above the Biotechnology median (#418 of 1341)
No single metric tells the full story. See the TSE:4571 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nano Holdings Inc formerly, Nano Mrna Co Ltd is engaged in the research and development of pharmaceuticals using micellar nanoparticle technology. The Group's business is a single segment that involves research and development, manufacturing, and sales of pharmaceuticals and other products, as well as related operations.
39GF Score
Get the complete analysis for TSE:4571
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4571 has been successfully added to your 
